Aroa Biosurgery’s Endoform® Platform Shown to Attract Stem Cells
- Further validation gained for Aroa’s proprietary Endoform®
platform with peer-reviewed publication in PLOS ONE.
- Study provides further insights on the ability of components
found within the Endoform® ECM platform technology to recruit stem
cells from surrounding healthy tissue to support soft tissue
- Further research to be undertaken on novel protein component
shown to attract stem cells.
Soft tissue regeneration company
Aroa Biosurgery Limited (ASX:ARX, ‘Aroa’ or the ‘Company’) has
gained further validation for Endoform®, its flagship extracellular
matrix (ECM), with a new study published in respected international
peer-reviewed journal PLOS ONE.
The paper, titled ‘A novel chemotactic factor derived from the
extracellular matrix protein decorin recruits mesenchymal stromal
cells in vitro and in vivo’, stems from a collaborative study
between the Aroa scientific team and scientists from Victoria
University in Wellington, New Zealand and Charles River
Laboratories in Germany.
Aroa’s lead scientist for the study, Dr Sandi Dempsey, said the
paper describes the ability of components found within the
Endoform® ECM platform technology to signal stem cells in
“Endoform® contains a vast number of proteins that interact with
a patient’s own cells to support the repair of damaged tissue in
different ways. This data suggests that one such mechanism occurs
by recruiting stem cells from the surrounding healthy tissue to
support soft tissue repair,” Dr Dempsey says.
Dr Barnaby May, co-author of the study and Aroa’s Vice President
of Research and Clinical Development said, “These recent findings
provide further peer-reviewed validation of how the Endoform® ECM
technology performs a critical role in soft tissue repair.
Endoform® is an advanced bioscaffold with a rich composition of
proteins that naturally occur in humans and help the body to
regenerate. That we have shown Endoform® attracts stem cells to the
site of tissue damage goes one step further towards unlocking the
full regenerative capacity of Endoform®.”
Aroa’s CEO Brian Ward said the findings build on extensive
pre-clinical and clinical research on Endoform® over the past 10
years as the company continues to focus on improving the rate and
quality of healing in complex wounds and soft tissue
The published study also identified a novel protein component
found in all tissue, dubbed ‘MayDay’ after the lead authors Dr
Barnaby May (Aroa) and Dr Darren Day (Victoria University of
‘MayDay’ was shown to communicate with stem cells and could play
an important role during normal soft tissue repair such as wound
healing, and further studies will be ongoing to understand the role
that ‘MayDay’ plays in soft tissue repair.
Endoform® is derived from ovine (sheep) forestomach and includes
a basement membrane layer and propria-submucosa (supportive
connective tissue). It acts as a scaffold to grow new tissue lost
or damaged through disease or injury, allowing the patient’s own
cells to grow into the matrix to build new tissue and re-establish
blood supply. As the patient continues to heal, this is replaced by
their own tissue.
Aroa has five commercial products approved for sale in the US
based on the Endoform® technology, which have been used in more
than four million procedures targeting chronic wounds, hernia, soft
tissue and breast reconstruction. Aroa has regulatory clearance in
more than 37 countries and a deep patent portfolio.
Authorised on behalf of the Aroa Biosurgery Board of
Directors by Brian Ward, CEO.
About Aroa Biosurgery:
Aroa Biosurgery is a soft-tissue regeneration company that
develops, manufactures, sells and distributes medical and surgical
products to improve healing in complex wounds and soft tissue
reconstruction. Committed to ‘unlocking regenerative healing for
everybody’, its products are developed from the Company’s
proprietary Endoform® technology platform, a novel extracellular
matrix biomaterial derived from ovine (sheep) forestomach.
Clinically proven with peer reviewed publications, Aroa’s products
have been used in more than four million procedures to date, with
distribution into its key market of the United States by Appulse
and Tela Bio. Founded in 2008, Aroa is headquartered in Auckland,
New Zealand and is listed on the Australian Securities Exchange
version on businesswire.com: https://www.businesswire.com/news/home/20200818005820/en/
Investor Simon Hinsley Investor Relations firstname.lastname@example.org +
61 401 809 653
Media Australia Matthew Wright
email@example.com +61 451 896 420
New Zealand Piet De Jong
firstname.lastname@example.org +64 21 812 766
Aroa Biosurgery (ASX:ARX)
Historical Stock Chart
From Dec 2020 to Jan 2021
Aroa Biosurgery (ASX:ARX)
Historical Stock Chart
From Jan 2020 to Jan 2021